| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2024 | ORSOBIO, INC. | 101 JEFFERSON DR | MENLO PARK | CA | 94025-1114 | SAN MATEO | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 000 | 3 | NIH | 11/19/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | ORSOBIO, INC. | 101 JEFFERSON DR | MENLO PARK | CA | 94025-1114 | SAN MATEO | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 000 | 1 | NIH | 2/12/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $999,999 ) |
| | 2024 | 2024 | ORSOBIO, INC. | 101 JEFFERSON DR | MENLO PARK | CA | 94025-1114 | SAN MATEO | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 000 | 3 | NIH | 8/16/2024 | $999,999 |
|
| Issue Date FY: 2023 ( Subtotal = $999,999 ) |
| | 2023 | 2023 | ORSOBIO, INC. | 101 JEFFERSON DR | MENLO PARK | CA | 94025-1114 | SAN MATEO | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 002 | 2 | NIH | 9/8/2023 | $999,999 |
| | 2023 | 2022 | ORSOBIO, INC. | 101 JEFFERSON DR | MENLO PARK | CA | 94025-1114 | SAN MATEO | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 001 | 1 | NIH | 8/18/2023 | $0 |
| | 2023 | 2022 | LIVER COMPANY INC., THE | 2671 MARSHALL DR | PALO ALTO | CA | 94303-3654 | SANTA CLARA | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 000 | 1 | NIH | 10/24/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $299,999 ) |
| | 2022 | 2022 | LIVER COMPANY INC., THE | 2671 MARSHALL DR | PALO ALTO | CA | 94303-3654 | SANTA CLARA | USA | R44DK135174 | TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy | 000 | 1 | NIH | 9/22/2022 | $299,999 |
|
|
